Changing Environments and Alternative Perspectives in Evaluating the Cost-Effectiveness of New Antipsychotic Drugs
Open Access
- 1 January 2003
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Schizophrenia Bulletin
- Vol. 29 (1) , 81-93
Abstract
This article examines the ways in which changes in the treatment environment and in measurement perspectives can affect the evaluation of cost-effectiveness of new medications. In three studies we reexamined data from a clinical trial of haloperidol and clozapine conducted from 1993 to 1996. The results of the studies are as follows: Study 1 found that clozapine treatment was associated with significantly reduced inpatient costs, and increased outpatient costs, suggesting that as systems use less inpatient care and more outpatient care, more effective medications may increase, rather than decrease, costs in sicker patients. Study 2 found that while provider assessments and standard measures favored clozapine over haloperidol, patient responses showed little evidence of a clinical advantage for clozapine and a less favorable side-effect profile. Study 3 found that while annual drug costs in the published trial were estimated to be $4,545 for a full year of clozapine treatment, atypical antipsychotic costs in 2000 were estimated to range from $1,254 to $3,016 in the Department of Veterans Affairs system, and from $2,221 to $8,147 in the private sector. In conclusion, cost-effectiveness, as evaluated in studies like CATIE, will increasingly need to be tied to service system contingencies, environments, and evaluation perspectives.Keywords
This publication has 13 references indexed in Scilit:
- The Effect of Institutional Fiscal Stress on the Use of Atypical Antipsychotic Medications in the Treatment of SchizophreniaJournal of Nervous & Mental Disease, 2001
- From Clinical Trials to Real-World Practice: Use of Atypical Antipsychotic Medication Nationally in the Department of Veterans AffairsMedical Care, 2001
- Cost-effectiveness of Clozapine Compared With Conventional Antipsychotic Medication for Patients in State HospitalsArchives of General Psychiatry, 2000
- Review of recent clinical studies with olanzapineThe British Journal of Psychiatry, 1999
- Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trialsSchizophrenia Research, 1999
- Initiating Clozapine Treatment in the Outpatient Clinic: Service Utilization and Cost TrendsPsychiatric Services, 1998
- Issues in estimating the cost of innovative mental health programsPsychiatric Quarterly, 1995
- Continuity of Care, Residence, and Family Burden in OhioThe Milbank Quarterly, 1994
- A quality of life interview for the chronically mentally illEvaluation and Program Planning, 1988
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970